“HER2/basal” tumors often are high-grade invasive ductal carcinomas67 or aggressive comedo-DCIS (ductal carcinoma in situ)70, and are innately resistant to Trastuzumab67,69. Here, ERBB2 is linked to ductal breast carcinoma in situ.